On Thursday, Progyny Inc (PGNY) stock saw a decline, ending the day at $15.55 which represents a decrease of $-0.31 or -1.95% from the prior close of $15.86. The stock opened at $15.84 and touched a ...

In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Kymera Therapeutics (KYMR – Research ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Pfizer and Merck's pneumococcal vaccines have been recommended for adults aged 50 and over in the US, potentially opening up ...

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The ...

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) have been given a consensus recommendation of “Hold” by ...

Read more: Swiss healthcare partners clinch new tariff system with flat rates This content was published on Oct 23, 2024 The International Monetary Fund has revised Switzerland’s growth forecast ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a ...

Viking Therapeutics (VKTX) stock gains 18% on strong Q3 results and promising updates on its obesity drug candidate VK2735.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.84% ...

Laboratory operator Labcorp beat Wall Street estimates for third-quarter profit and revenue on Thursday as strong demand for ...